GENENTECH, INC.

Graft versus Host Disease Market to grow at 9.9% CAGR (2020-2034), driven by branded therapies, strong pipeline, and increased awareness. Market size in the US was $1 billion in 2023, expected to grow at 7.4% CAGR (2024-2034). Emerging therapies like Axatilimab and CSL964 to transform market. Key companies include Equillium, Biocon, Takeda, and CSL Behring.

The graft versus host disease market is growing due to the adoption of branded therapies like JAKAFI, IMBRUVICA, ORENCIA, and REZUROCK, a strong pipeline with over 10 new drugs expected to launch, and increased awareness of GvHD management. Innovative treatments and ongoing research aim to address unmet needs in this complex condition.

Study explores the burden of multiple food allergies on daily activities and QoL, finding social limitations, stress, and restrictions on freedom, impacting both individuals and families.

Vir Biotechnology appoints Jason O'Byrne as EVP and CFO, effective October 2, 2024, and Brent Sabatini as principal accounting officer, effective October 1, 2024.